Survival outcomes of robotic-assisted laparoscopy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis

• Published in: Gynecologic oncology Vol. 174; pp. 55 - 67
• Main Authors: Fu, Hanlin, Zhang, Jiahui, Zhao, Shiyi, He, Nannan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023
• Subjects: Conventional laparoscopy; Endometrial cancer; Endometrial Neoplasms; Endometrium; Female; Hematology, Oncology, and Palliative Medicine; Humans; Laparoscopy - adverse effects; Laparotomy; Laparotomy - adverse effects; Long-term survival; Obstetrics and Gynecology; Robotic Surgical Procedures; Robotic-assisted laparoscopy; Long-term survival; Conventional laparoscopy; Endometrial cancer; Laparotomy; Robotic-assisted laparoscopy
• ISSN: 0090-8258; 1095-6859; 1095-6859
• DOI: 10.1016/j.ygyno.2023.04.026

Robotic-assisted laparoscopy (RALS) has gained widespread acceptance in the field of gynecological oncology. However, whether the prognosis of endometrial cancer after RALS is superior to conventional laparoscopy (CLS) and laparotomy (LT) remains inconclusive. Therefore, the aim of this meta-analysis was to compare the long-term survival outcomes of RALS with CLS and LT for endometrial cancer. A systematic literature search was conducted on electronic databases (PubMed, Cochrane, EMBASE and Web of Science) until May 24, 2022, followed by a manual search. Based on inclusion and exclusion criteria, publications investigating long-term survival outcomes after RALS vs CLS or LT in endometrial cancer patients were collected. The primary outcomes included overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS) and disease-free survival (DFS). Fixed effects models or random effects models were employed to calculate the pooled hazard ratios (HRs) and 95% confidence intervals (CIs) as appropriate. Heterogeneity and publication bias were also assessed. RALS and CLS had no difference in OS (HR = 0.962, 95% CI: 0.922–1.004), RFS (HR = 1.096, 95% CI: 0.947–1.296), and DSS (HR = 1.489, 95% CI: 0.713–3.107) for endometrial cancer; however, RALS was significantly associated with favorable OS (HR = 0.682, 95% CI: 0.576–0.807), RFS (HR = 0.793, 95% CI: 0.653–0.964), and DSS (HR = 0.441, 95% CI: 0.298–0.652) when compared with LT. In the subgroup analysis of effect measures and follow-up length, RALS showed comparable or superior RFS/OS to CLS and LT. In early-stage endometrial cancer patients, RALS had similar OS but worse RFS than CLS. RALS is safe in the management of endometrial cancer, with long-term oncological outcomes equivalent to CLS and superior to LT. •It is of great interest to evaluate the long-term safety of minimally invasive surgery in gynecologic oncology.•RALS and CLS had equivalent survival outcomes for endometrial cancer.•Compared with laparotomy, RALS was significantly associated with favorable OS, RFS and DSS in endometrial cancer.•Providing non-inferior survival outcomes to CLS and LT, RALS is oncologically safe for endometrial cancer.